Medigene AG is an innovative immuno-oncology platform company focused on developing T cell receptor (TCR)-guided therapies aimed at effectively targeting and eliminating cancer. Central to its approach is the proprietary End-to-End (E2E) Platform, which is designed to generate optimal TCRs characterized by their specificity, sensitivity, and safety (3S attributes). This platform supports various therapeutic modalities, including TCR-engineered T cell therapies (TCR-T), TCR-guided T cell engagers, and TCR-natural killer cell therapies. Medigene's lead candidate, MDG1015, exemplifies this technology, combining a third-generation TCR-T therapy targeting the NY-ESO-1 antigen with a PD1-41BB costimulatory switch protein to enhance therapeutic efficacy while maintaining a favorable safety profile.

In addition to its core TCR technology, Medigene has developed advanced systems such as the UniTope and TraCR technologies, which facilitate the tagging and tracking of recombinant TCRs (rTCRs) within TCR-T therapies. These systems enable precise identification and monitoring of TCR-T cells, ensuring robust quality control during drug product development and enhancing patient safety. By integrating these innovative technologies into its E2E Platform, Medigene aims to optimize the discovery and development of TCR therapies, ultimately advancing its mission to provide effective treatment options for various cancer types.

Germany

Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.

Medigene AG

Company Details